Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of once-weekly RO7795068 in adults with obesity or overweight without type 2 diabetes
2025-523104-71-00Phase 3Authorised
- Sponsor
- Roche
- Start
- May 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in obesity and Overweight comparing RO7795068 with Placebo (2 arms). Primary endpoint: Percent change from baseline in body weight at Week 72. Planned start May 2026; status: authorised.
02
Drugs
zilebesiran
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2025-523104-71-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523104-71-00.